Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

ConditionMalignant Tumour

Trial statusRecruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age18-90

SponsorFirst Affiliated Hospital of Fujian Medical University

About this trial

As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

68Ga-dPNE
18F-FDG

Treatment groups

30 Participants

are divided into 2 treatment groups

Sponsors and collaborators

First Affiliated Hospital of Fujian Medical University

Lead sponsor

Source ClinicalTrials.gov